Blasts from the past

Blasts from the past

While Ligand Pharmaceuticals Inc.'s planned takeout of Neurogen Corp. for $11 million in stock may look like small potatoes on paper, the acquirer thinks the deal is a key step towards its goal of becoming cash flow neutral in 2010...